| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Azido-PEG3-t-butyl ester is classified as an ADC linker, a PROTAC linker, and a click chemistry reagent. The azide group can react with alkyne, BCN, or DBCO via click chemistry to yield a stable triazole linkage. The tert-butyl ester protects the carboxyl group for controlled deprotection and conjugation.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [2].
Azido-PEG3-t-butyl ester is used as a linker in the synthesis of ADCs and PROTACs. It is not typically evaluated for direct biological activity as a standalone compound. Its role is to provide a PEG spacer and reactive groups for conjugation. |
| ln Vivo |
Azido-PEG3-t-butyl ester is not typically evaluated for in vivo activity as a standalone compound. Its role is in the synthesis of ADCs or PROTACs, which are then evaluated in vivo. The PEG spacer can improve the pharmacokinetic properties of the conjugated molecules.
|
| Enzyme Assay |
Azido-PEG3-t-butyl ester is a chemical reagent, and its purity and identity are confirmed using analytical techniques such as NMR and HPLC. It is not typically used in enzyme or receptor binding assays. Its reactivity as a click chemistry reagent can be assessed by reacting it with alkyne-containing compounds.
|
| Cell Assay |
Azido-PEG3-t-butyl ester is not typically used in cell-based assays as a standalone compound. Its primary application is in the synthesis of ADCs or PROTACs, which are then tested in cell-based assays for their activity.
|
| Animal Protocol |
Azido-PEG3-t-butyl ester is not typically used in in vivo animal studies as a standalone compound. It is used to synthesize ADCs or PROTACs, which are then evaluated in animal models for their therapeutic efficacy and safety.
|
| ADME/Pharmacokinetics |
Azido-PEG3-t-butyl ester has a molecular formula of C13H25N3O5 and a molecular weight of 303.35. It contains a PEG3 spacer with an azide group and a tert-butyl ester. It is a monodisperse PEG derivative.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Azido-PEG3-t-butyl ester are not detailed in the available literature. As a linker used in ADC or PROTAC research, its toxicity is typically assessed as part of the final conjugated product. Standard safety precautions should be taken when handling this compound.
|
| References |
[1]. Yongxin Robert ZHAO, et al. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers. WO2018086139A1.
[2]. Peng L, et al. Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation. ACS Med Chem Lett. 2019 Apr 12;10(5):767-772. |
| Additional Infomation |
Azido-PEG3-t-butyl ester is a PEG linker used in the synthesis of ADCs and PROTACs. It is a click chemistry reagent containing an azide group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-containing molecules. It is a research tool for the development of targeted therapies.
|
| Molecular Formula |
C13H25N3O5
|
|---|---|
| Molecular Weight |
303.35500
|
| Exact Mass |
303.179
|
| CAS # |
252881-73-5
|
| PubChem CID |
60146206
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
1.531
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
21
|
| Complexity |
324
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)CCOCCOCCOCCN=[N+]=[N-]
|
| InChi Key |
QUSLQIYNPWASRR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H25N3O5/c1-13(2,3)21-12(17)4-6-18-8-10-20-11-9-19-7-5-15-16-14/h4-11H2,1-3H3
|
| Chemical Name |
tert-butyl 3-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2964 mL | 16.4821 mL | 32.9641 mL | |
| 5 mM | 0.6593 mL | 3.2964 mL | 6.5928 mL | |
| 10 mM | 0.3296 mL | 1.6482 mL | 3.2964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
